Denise Braendgaard: We are Now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Denise Braendgaard, General Manager of Novo Nordisk Haemophilia Foundation, shared a post by Novo Nordisk Haemophilia & Haemoglobinopathies Foundation on LinkedIn:
”The day has finally arrived and I can’t hide my excitement: we are waking up to new horizons.
After years of preparation by our Council and Team – and inspired by our incredible partners – we are immensely proud to announce that we are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation.
It is much more than adding one word.
It represents hope for people affected by haemoglobinopathies – specifically sickle cell disease and thalassaemia – in low and middle income countries who will benefit from our programmes. At the same time, it reaffirms our unwavering commitment to haemophilia.
It is an expansion of our vision and scope, a bold declaration of our continued, long-term dedication after 20 years of Impacting Care. Together.”
Quoting Novo Nordisk Haemophilia & Haemoglobinopathies Foundation’s post:
”We are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder, Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.”
Keep up with Hemostasis Today.
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
-
Apr 23, 2026, 17:18Katarina Ziakova: The WFH Shared Decision – Making Tool Is Driving Critical Conversations in Haemophilia Care
-
Apr 23, 2026, 17:14Paulus Kirchhof: Can We Improve Prevention of Cardiovascular Diseases?
-
Apr 23, 2026, 17:08Wolfgang Miesbach: 5‑Year Gene Therapy Data from WFH Congress 2026
-
Apr 23, 2026, 17:05Veronica Sanchez: The 2026 Guideline on the Management of Dyslipidemia